The 20 Best Olfactory Neuroblastoma Doctors Near Me in Lutherville, MD

Nyall London has a unique clinical practice focused on the care of patients with sinonasal and skull base cancers. As one of the few surgeons trained in both head and neck cancer surgery, as well as rhinology and skull base surgery, he offers patients comprehensive sinonasal tumor surgical care, including open and endoscopic approaches as well as neck dissection surgery. Dr. London has developed notable patient education events about the multidisciplinary and long-term care of patients with sinonasal malignancies. Additionally, he is an innovator of clinical trials for these rare tumors, with open clinical trial options available and multiple others in development. Internationally recognized for his expertise in the care of patients with sinonasal and skull base cancers, Dr. London was an associate editor for the first international consensus statement on sinonasal tumors, and was appointed president of the International Network for Sinonasal Cancer Research (2024–26). He directs a research laboratory at the National Cancer Institute/National Institutes of Health focused on therapeutic advances and mechanisms of sinonasal tumorigenesis. Dr. London has published more than 130 peer-reviewed research articles, reviews and book chapters, including co-first author publications in Nature, Nature Medicine, Science Translational Medicine and Nature Cell Biology. He earned his medical and doctoral degrees from the University of Utah, and completed his residency in otolaryngology–head and neck surgery at Johns Hopkins. He also accomplished a fellowship in open and endoscopic head and neck and skull base surgery at The Ohio State University, under the direction of Dr. Ricardo Carrau. Dr. London is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Olfactory Neuroblastoma, Sinus Cancer, Teratocarcinosarcoma, Endoscopy, and Craniectomy. Dr. London is board certified in Head And Neck Surgery.

Dr. Gary Gallia's specialty is endoscopic endonasal surgical approaches to skull base pathologies with a focus on neurosurgical oncology. He utilizes the latest techniques in preoperative imaging, computer-guided surgical navigation, intraoperative monitoring, and minimally invasive and Neuroendoscopy approaches in the management of patients with benign and malignant brain tumors, metastatic tumors to the brain, skull base neoplasms, and pituitary tumors. He is the director of the Neurosurgery Skull Base Center and surgical director of the Johns Hopkins Pituitary Center. Dr. Gary Gallia graduated summa cum laude from the Gibbons Scholar MD/PhD program at Jefferson Medical College and Thomas Jefferson University. He completed his general surgery internship at The Johns Hopkins Hospital where he was awarded surgical intern of the year. He then completed his neurological surgery residency and a postdoctoral fellowship in neuro-oncology at The Johns Hopkins Hospital. Following residency, he completed a minimally invasive and endoscopic neurosurgery fellowship with Dr. Charles Teo at the Prince of Wales Private Hospital and Sydney Children's Hospital in Sydney, Australia. Dr. Gallia is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Olfactory Neuroblastoma, Chordoma, Pituitary Tumor, Awake Craniotomy, and Craniectomy. Dr. Gallia is board certified in American Board Of Neurological Surgery.

Dr. Masaru Ishii graduated from University of Pennsylvania Perelman School of Medicine. His clinical specialties include surgical management of nasal airway obstruction, chronic sinusitis and sinonasal tumors, as well as endoscopic surgery for skull base tumors. Dr. Ishii is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Olfactory Neuroblastoma, Prolactinoma, Cerebrospinal Fluid Leak, Septoplasty, and Mastoidectomy. Dr. Ishii is board certified in Head And Neck Surgery.

Charalampos Floudas is an Oncologist practicing medicine in Bethesda, Maryland. Dr. Floudas is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Olfactory Neuroblastoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Gliomatosis Cerebri.

James Gulley is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Gulley is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Olfactory Neuroblastoma, Chordoma, Urothelial Cancer, and Orchiectomy.

Wayne Koch is a national and international leader in head and neck oncologic surgery, caring for patients with cancers of the oral cavity, salivary gland, larynx, hypopharynx, oropharynx and thyroid. Among Dr. Koch's landmark publications are studies demonstrating how key molecular events such as p53 mutation and human papillomavirus (HPV) contribute to the development of head and neck cancer. His peer-reviewed publications include six articles in the New England Journal of Medicine. Dr. Koch is also involved in humanitarian outreach focused on training surgeons in several African nations. He has served as president of the American Head and Neck Society, the national organization of head and neck cancer surgeons in the USA. Dr. Koch is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Human Papillomavirus Infection, Laryngectomy, and Gastrostomy. Dr. Koch is board certified in Head And Neck Surgery.

Clint Allen is an Otolaryngologist practicing medicine in Bethesda, Maryland. Dr. Allen is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Recurrent Respiratory Papillomatosis, Head and Neck Squamous Cell Carcinoma (HNSCC), Hearing Loss, Human Papillomavirus Infection, and Endoscopy. Dr. Allen is board certified in Head And Neck Surgery.

Dr. Ana Kiess's clinical focus is on the treatment of prostate cancer and head and neck cancers with external beam radiotherapy and radiopharmaceutical therapies. Her research concentrates on the integration of new radiopharmaceutical therapies and dosimetry techniques into the clinic. Dr. Kiess received her bachelors of science degree in chemical engineering from the University of Virginia, after which she obtained a doctorate of medicine and a doctorate of philosophy degree in biomedical engineering from Duke University. Following medical school, she matriculated to the resident staff at Memorial Sloan Kettering Cancer Center, receiving extensive oncologic training and research experience. She also completed a postdoctoral research fellowship at Johns Hopkins University in the Department of Radiology. Make A Gift. Dr. Kiess is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. She is also highly rated in 31 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Laryngeal Cancer, Acinic Cell Carcinoma of Salivary Glands, Gastrostomy, and Adenoidectomy. Dr. Kiess is board certified in American Board Of Radiology.

Dr. Tanguy Seiwert is an oncologist in Baltimore, caring for patients with head and neck cancer. He serves as the director of the Head and Neck Cancer Oncology Disease Program and the co-director of the Bloomberg~Kimmel Institute for Immunotherapy at the Head and Neck Cancer Program at the Johns Hopkins School of Medicine. Dr. Seiwert earned his M.D. at Johannes Gutenberg Universität in Mainz, Germany. He completed his residency at the Duke University School of Medicine and performed a fellowship in hematology/oncology at the University of Chicago Medicine Mitchell Hospital-Hyde Park. Dr. Seiwert joined the Johns Hopkins faculty in 2019. Prior to joining Johns Hopkins, Dr. Seiwert was director of the Head and Neck Cancer Program at the University of Chicago. Dr. Seiwert’s research interests include immunologic and genomic profiling. He has given numerous invited talks on head and neck cancer both nationally and internationally. Dr. Seiwert served as chief editor for Frontiers in Head and Neck Cancer and as an editorial board member for the Journal of Clinical Oncology and Oral Oncology. He is a reviewer for multiple medical journals, including Lancet Oncology, Annals of Oncology and Clinical Cancer Research. He has been recognized by the American Association for Clinical Oncology for multiple Merit Awards and a Young Investigator Award. He was a member of the NCI Head and Neck Cancer Steering Committee, and is a member of the American Association for Clinical Oncology, the Society for Immunotherapy of Cancer, and the European Society of Clinical Oncology. Dr. Seiwert is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Glioma, Laryngeal Cancer, Tongue Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy. Dr. Seiwert is board certified in American Board Of Internal Medicine.

Rodney Taylor is a General Surgeon practicing medicine in Baltimore, Maryland. Dr. Taylor is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Teratocarcinosarcoma, Olfactory Neuroblastoma, Sinus Cancer, Laryngectomy, and Tissue Biopsy.

Kevin Cullen is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Cullen is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Teratocarcinosarcoma, Olfactory Neuroblastoma, and Laryngeal Cancer.

Christine Gourin, M.D. M.P.H., is a head and neck surgical oncologist and palliative medicine specialist who treats patients with head and neck tumors, including tumors of the skin, melanoma, oral cavity, larynx, oropharynx, neck, salivary glands, sinuses, and skull base. Dr. Gourin received her medical degree from the State University of New York-Health Science Center at Brooklyn/Downstate Medical Center. Dr. Gourin trained in General Surgery and Otolaryngology-Head and Neck Surgery at the University of Vermont, followed by a fellowship in Advanced Head and Neck Oncologic Surgery at the University of Pittsburgh and a fellowship in Hospice and Palliative Medicine at Johns Hopkins University. She has authored over 200 peer-reviewed journal articles, 24 book chapters and two books: Medical and Surgical Management of Thyroid and Parathyroid Diseases and The Johns Hopkins Patient Guide to Head and Neck Cancer. She is on the Editorial Board of The Laryngoscope and is a reviewer for numerous other head and neck surgery journals. Dr. Gourin is a nationally and internationally recognized expert in quality of care and outcomes with a lifelong interest in improved symptom management, communication, access to high-quality affordable care, and palliative medicine in head and neck cancer. She has an active head and neck surgical oncology practice and has been named to America’s Top Physicians and Best Doctors in America annually since 2005. She is the Director of the Johns Hopkins Head and Neck Cancer Supportive Care Clinic. Dr. Gourin is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Tongue Cancer, Laryngectomy, and Gastrostomy. Dr. Gourin is board certified in American Board Of Internal Medicine and Head And Neck Surgery.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is board certified in American Board Of Internal Medicine.

Dr. Andrew Lane is the Director of the Johns Hopkins Sinus Center and performs the full range of endoscopic sinus procedures, including transnasal skull base and orbital surgeries. He is dedicated to providing cutting-edge care to his patients and developing new therapies for chronic rhinosinusitis through his clinical and basic science research. He is the longest practicing sinus specialist with advanced fellowship training in the Baltimore/Washington region, with two decades of experience in the medical and surgical management of challenging sinus disease. Dr. Lane received a bachelor's degree from Harvard University and an M.D. from the University of Pennsylvania School of Medicine. He completed his internship in general surgery and residency in Otolaryngology-Head and Neck Surgery at the University of North Carolina at Chapel Hill. He came to Johns Hopkins in 2001, after completing a fellowship in advanced endoscopic sinus surgery techniques at the University of Pennsylvania. Dr. Lane maintains a busy clinical practice while also running an NIH-funded laboratory. His research investigates the causes and potential treatments for chronic rhinosinusitis with nasal polyps, as well as how inflammation affects the sense of smell. An author of over 140 published articles and book chapters, he frequently presents his surgical and research results at national and international meetings. He has earned several prestigious awards for his research about nasal polyps and olfactory loss. Dr. Lane is Editor-in-Chief of Current Otorhinolaryngology Reports, Associate Editor of the American Journal of Rhinology and Allergy, and an Editorial Board member of the International Forum of Allergy & Rhinology. He has served on the Board of Directors of the American Rhinologic Society and chaired the Rhinology and Paranasal Sinus Committee of the American Academy of Otolaryngology – Head and Neck Surgery. He is the Rhinology section leader for the Triological Society’s Best Practice committee. Dr. Lane is often invited to speak at outside medical institutions and regularly conducts media interviews about nasal and sinus issues. Dr. Lane is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Nasal Polyps, Sinusitis, Endoscopy, and Septoplasty. Dr. Lane is board certified in Head And Neck Surgery.

Nicholas Rowan is a sinus and skull base surgeon who helps patients with conditions such as deviated septum, nasal congestion, nasal obstruction, sinus pressure and chronic sinusitis, as well as complex issues like loss of smell, sinus cancers, cerebrospinal fluid (CSF) leaks and tumors that grow near the brain. He frequently performs nasal polyp surgery and endoscopic sinus procedures, using minimally invasive approaches to help patients recover quickly and breathe more easily. For tumors of the skull base or brain, he works closely with neurosurgeons and cancer specialists to deliver coordinated, comprehensive care. Dr. Rowan’s research is focused on improving patients’ quality of life and long-term outcomes after sinus and skull base surgery. A major part of his work involves studying the sense of smell — not just how to restore it, but how it reflects overall health. He explores how smell loss may be an early warning sign of unhealthy aging, frailty or cognitive decline. Through this work, he aims to better understand the biological link between the nose and brain, and what it can reveal about a person’s health trajectory. He works closely with biomedical engineers to develop novel diagnostic and therapeutic technologies, and he is the principal investigator of multiple ongoing clinical trials that are testing new treatments for chronic sinusitis and nasal polyps. A frequent speaker at national and international conferences, Dr. Rowan shares insights from his innovative research and surgical experience. He leads courses and delivers lectures on advanced sinus and skull base techniques, smell loss and the evolving science behind how nasal health connects to overall well-being. Dr. Rowan is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Sinusitis, Anosmia, Pituitary Tumor, Endoscopy, and Septoplasty. Dr. Rowan is board certified in Head And Neck Surgery.

Maie John is an Otolaryngologist practicing medicine in Baltimore, Maryland. Dr. John is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. She is also highly rated in 25 other conditions, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Melanoma, Glossectomy, and Gastrostomy. Dr. John is board certified in Head And Neck Surgery.

Dr. Kofi Derek Owusu Boahene is a professor of otolaryngology-head and neck surgery and dermatology at the Johns Hopkins University School of Medicine. He is the Director of the Division of Facial Plastics and Reconstructive Surgery and the director for the facial plastics fellowship training program. His practice encompasses the entire spectrum of facial plastic and reconstructive surgery including cosmetic and reconstructive aspects. Dr. Boahene is a leading expert in facial paralysis surgery and facial nerve injuries and has pioneered innovative treatment protocols and surgical techniques in facial reanimation. He is the director of the Johns Hopkins Facial Nerve center dedicated to restoring facial balance, symmetry and animation to those who have suffered from facial paralysis and facial nerve disorders. As an expert microsurgeon, Dr. Boahene routinely performs some of the most complex facial reconstruction procedures on the face including rebuilding of an entire nose, lip, jaw and facial defects resulting from cancer treatment, traumatic injuries or as a result of birth defects. He uses cutting edge 3-D technology, image-guided technology and tissue transplanted from other parts of the body to restore or replace missing tissues. He is a key member of the Johns Hopkins facial transplant program. His cosmetic experience is broad and draws from patients across the globe. He routinely performs rhinoplasties, eyelid surgery, face lifts and other facial enhancing procedures. As a skull base surgeon, Dr. Boahene has pioneered minimally invasive techniques for removal of skull base and brain tumors, repairing CSF leaks and has authored a major textbook on this subject. Dr. Boahene received his undergraduate degree from the University of Central Arkansas. He graduated summa cum laude from Meharry Medical College in Nashville, Tennessee, completed a five-year surgical residency training program in otolaryngology-head and neck surgery at the Mayo Clinic in Rochester, Minnesota, and received fellowship training in facial plastic and reconstructive surgery at the University of Minnesota. As the recipient of the prestigious Mayo Brothers Distinguished Fellowship Award, Dr. Boahene was awarded additional craniofacial surgery training in Adelaide, Australia. He also received the Jack R. Anderson Prize for Scholastic Excellence for attaining the highest score nationally on the American Academy of Facial Plastic and Reconstructive Surgery certification exam. Dr. Boahene serves as on the Board of Governors or the American Academy Facial Plastic and Reconstructive Surgery. He is a member of several professional organizations, including the American Academy of Facial Plastic and Reconstructive Surgery and the American Academy of Otolaryngology-Head and Neck Surgery. In 1993, Dr. Kofi Boahene received the Alpha Omega Alpha Medical. Dr. Boahene is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Facial Paralysis, Bell's Palsy, Recurrent Peripheral Facial Palsy, Septoplasty, and Gastrostomy. Dr. Boahene is board certified in American Board Of Facial Plastic And Reconstructive Surgery and Head And Neck Surgery.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Pancreaticoduodenectomy. Dr. Lipson is board certified in American Board Of Internal Medicine.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Pancreatic Cancer. Dr. Sharfman is board certified in American Board Of Internal Medicine.

Wojtek Mydlarz, director of Johns Hopkins Head and Neck Surgery in the National Capital Region, specializes in the treatment of benign and malignant tumors of the head and neck, including the upper aerodigestive tract, salivary glands, skull base, thyroid, skin and soft tissue. Dr. Mydlarz is a medical officer and a clinical and research collaborator in the head and neck surgery branch of the National Institutes of Health (NIH). His research interests include evaluating both surgical and nonsurgical treatment outcomes in patients with head and neck cancer. He is interested in the complex molecular biology of head and neck cancer, as well as potential clinical applications of novel targeted cancer therapies. He is actively involved in clinical trial development and implementation at the NIH and Johns Hopkins. After earning his medical degree from the Johns Hopkins University School of Medicine, Dr. Mydlarz completed his internship and residency in otolaryngology–head and neck surgery at The Johns Hopkins Hospital. Additionally, he completed a Science of Clinical Investigation Training Program at Johns Hopkins Bloomberg School of Public Health and specialized fellowship training in head and neck surgical oncology at the University of Texas MD Anderson Cancer Center. Dr. Mydlarz has contributed to numerous professional publications, authored a variety of articles and book chapters, and has been invited to give many lectures. He serves on the editorial board for Oral Oncology and Laryngoscope Investigative Otolaryngology, and is a journal reviewer for Oral Oncology, Head and Neck, Laryngoscope and JAMA Otolaryngology–Head and Neck Surgery. Dr. Mydlarz is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Salivary Gland Tumors, Laryngectomy, and Glossectomy. Dr. Mydlarz is board certified in Head And Neck Surgery.